Singulair 5mg 28 chewable tablets — Made in Great Britain — Free Delivery

When Singular® is used as an adjunct therapy to inhaled corticosteroids, Singular® should not suddenly replace inhaled corticosteroids.

Animal studies have shown no deleterious effects on pregnancy or embryonic / fetal development. The available data from published prospective and retrospective cohort studies using montelukast in pregnant women who assess significant birth defects in children have not established the risk associated with the use of the preparation. The available studies have methodological limitations, including small sample sizes, in some cases retrospective data collection, and incompatible comparison groups.

Studies in rats have shown that montelukast passes into milk. It is not known whether montelukast is excreted in breast milk in women. This medication should only be used during breastfeeding if it is considered absolutely necessary.

Applied to children aged 6 to 14 years.

It is not expected that montelukast will affect the patient's ability to drive vehicles or other machinery. However, drowsiness or dizziness has been reported very rarely.

There is no special information on the treatment of an overdose with the preparation "Singular®". In studies of chronic asthma, montelukast was prescribed in doses up to 200 mg / day to adult patients for 22 weeks, and in short-term studies - up to 900 mg / day for about one week, while clinically important adverse reactions did not occur. In post-marketing use and in clinical trials, there have been reports of acute overdose of the preparation "Singular®". These included the administration of the preparation in adults and children in doses exceeding 1000 mg (approximately 61 mg / kg in a child aged 42 months). The obtained clinical and laboratory data were consistent with the safety profile in adult patients and children. In most cases of overdose, no adverse reactions were reported. The most common adverse reactions were observed, which corresponded to the safety profile of the preparation "Singular" and included: abdominal pain, drowsiness, thirst, headache, vomiting and psychomotor hyperactivity.

It is not known whether montelukast is excreted by peritoneal dialysis or hemodialysis.

Montelukast has been evaluated in clinical trials: chewable tablets 5 mg were used by approximately 1,750 children aged 6 to 14 years.

In clinical studies, the following adverse reactions were observed frequently (from ≥ 1/100 to <1/10) in patients treated with montelukast, and also with a greater frequency than in patients treated with placebo.

Nervous system disorders: headache.

Store in its original packaging at a temperature not exceeding 30 ° C, out of the reach of children.

Shelf life is 2 years.